Future of Penumbra | Quantumrun

Future of Penumbra

The Penumbra, Inc has its headquarters based in Alameda, California. This corporation is a worldwide interventional therapy company, which aims to design, develop, manufacture, and market ground-breaking medical devices. The Penumbra, Inc has a wide scale portfolio of items to address medical illness with challenging and noteworthy clinical requirements across two chief markets, i.e., peripheral vascular and neuro. The medical conditions that these products address among others are hemorrhagic stroke, ischemic stroke, and a variety of peripheral vascular problems, which can be tackled through embolization and thrombectomy procedures.

Home Country: 
United States
Industry: 
Medical devices
Industry vulnerability to disruption: 

<p>Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:</p>

<p>*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.
*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.<br />
*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.<br />
*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.<br />
*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.<br />
*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.<br />
*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.<br />
*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.</p>

Total patents held: 
10
Number of patents field last year: 
1
Ranking List: 
780
Ranking List: 
2017 Quantumrun Global 1000
Ranking List: 
2017 Quantumrun US 500
99
Ranking List: 
2017 Quantumrun Silicon Valley 100
Market Revenue Country: 
Market country 
United States
Revenue from country 
0.67
Prod/Serv name revenue: 
Prod/Serv name: 
Neuro
Prod/Serv revenue: 
185533000
Prod/Serv name: 
Peripheral vascular
Prod/Serv revenue: 
77784000
Founded: 
2004
Company Name: 
Penumbra
Sector: 
Revenue: 
263317000
3y average revenue: 
191640667
Operating expenses: 
172179000
3y average expenses: 
123963667
Company profile data note: 
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.
Global employee count: 
1500
Number of domestic locations: 
1
Funds in reserve: 
13236000
Investment into R&D: 
23875000
create term: 
#780 | 2017 Quantumrun Global 1000
#99 | 2017 Quantumrun Silicon Valley 100

The Penumbra, Inc has its headquarters based in Alameda, California. This corporation is a worldwide interventional therapy company, which aims to design, develop, manufacture, and market ground-breaking medical devices. The Penumbra, Inc has a wide scale portfolio of items to address medical illness with challenging and noteworthy clinical requirements across two chief markets, i.e., peripheral vascular and neuro. The medical conditions that these products address among others are hemorrhagic stroke, ischemic stroke, and a variety of peripheral vascular problems, which can be tackled through embolization and thrombectomy procedures.

Home country:
United States
Sector:
Health Care
Industry:
Medical devices
Website:
Founded:
2004
Global employee count:
1,500

Financial Health

Revenue
$263,317,000 USD
3y average revenue
$191,640,667 USD
Operating expenses
$172,179,000 USD
3y average expenses
$123,963,667 USD
Funds in reserve
$13,236,000 USD
#1 Market country
United States
% of revenue from country #1
0.67%

Asset Performance

#1 Product/Service/Dept. name
Neuro
#1 Product/Service revenue
$185,533,000 USD
#2 Product/Service/Dept. name
Peripheral vascular
#2 Product/Service revenue
$77,784,000 USD

Innovation assets and Pipeline

Investment into R&D
$23,875,000 USD
Total patents held
10
Number of patents field last year
1
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.

Disruption Vulnerability

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.
*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.

*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.

*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.

*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.

*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.

*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.

*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.